Abstract:PURPOSE:Novel Bayesian adaptive designs provide an effective way to improve clinical trial efficiency. These designs are superior to conventional methods, but implementing them can be challenging. The aim of this article was to describe what we learned while applying a novel Bayesian phase I-II design in a recent trial.METHODS:The primary goal of the trial was to optimize radiation therapy (RT) dose among three levels (low, standard, and high), given either with placebo (P) or an investigational agent (A), for treating locally advanced, radiation-naive pancreatic cancer, deemed appropriate for RT rather than surgery. Up to 48 patients were randomly assigned fairly between RT plus P and RT plus A, with RT dose-finding done within each arm using the late-onset efficacy-toxicity design on the basis of two coprimary end points, tumor response and dose-limiting toxicity, both evaluated at up to 90 days. The random assignment was blinded, but within each arm, unblinded RT doses were chosen adaptively using software developed within the institution.RESULTS:Implementing the design involved double-blind balance-restricted random assignment, real-time assessment of patient outcomes to evaluate the efficacy-toxicity trade-off for each RT dose in each arm to optimize each patient's RT dose adaptively, and transition from a single-center trial to a multicenter trial. We present lessons learned and illustrative documentation.CONCLUSION:Implementing novel Bayesian adaptive trial designs requires close collaborations between physicians, pharmacists, statisticians, data managers, and sponsors. The process is difficult but manageable and essential for efficient trial conduct. Close collaboration during trial conduct is a key component of any trial that includes real-time adaptive decision rules.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

A Bayesian Phase I/II Trial Design for Immunotherapy

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Bayesian phase II adaptive randomization by jointly modeling efficacy and toxicity as time-to-event outcomes

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials

Bayesian phase I/II adaptively randomized oncology trials with combined drugs

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

A Bayesian Dynamic Model‐Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials